• 1
    Hirschel B., Opravil M. (1999) The year in review: antiretroviral treatment. AIDS 13: S17787.
  • 2
    Palella F.J., Jr., Delaney K.M., Moorman A.C., et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 85360.
  • 3
    Condra J.H., Schleif W.A., Blahy O.M., et al . (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374: 56971.
  • 4
    Larder B.A., Kemp S.D. (1989) Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 11558.
  • 5
    Coffin J.M. (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267: 48389.
  • 6
    Gaschen B., Taylor J., Korber B., et al . (2002) Diversity consideration in HIV-1 vaccine selection. Science 296: 235460.
  • 7
    Charpentier C., Nora T., Tenaillon O., Clavel F., Hance A.J. (2006) Extensive recombination among Human Immunodeficiency Virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. J Virol 80: 247282.
  • 8
    Doukhan L., Delwart E. (2001) Population genetic analysis of the protease locus of human immunodeficiency virus type 1 quasispecies undergoing drug selection, using a denaturing gradient-heteroduplex tracking assay. J Virol 75: 672936.
  • 9
    Liu S.L., Rodrigo A.G., Shankarappa R, et al . (1996) HIV quasispecies and resampling. Science 273: 4156.
  • 10
    Nei M., Gojobori T. (1986) Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol 3: 41826.
  • 11
    Johnson V.A., Brun-Vezinet F., Clotet B., et al . (2008) Update of the drug resistance mutations in HIV-1: December 2008. International AIDS Society-USA. Topics HIV Med 16: 13845.
  • 12
    Frater A.J., Beardall A., Ariyoshi K., et al . (2001) Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 15: 14931502.
  • 13
    Erickson J.W., Gulnik S.V., Markowitz M. (1999) Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS 13(Suppl A): S189204.
  • 14
    Charpentier C., Dwyer D.E., Mammano F., Lecossier D., Clavel F., Hance A.J. (2004) Role of minority populations of human immunodeficiency virus type1 in the evolution of viral resistance to protease inhibitors. J Virol 78: 423447.
  • 15
    Lori F., Maserati R., Foli A., Seminari E., Timpone J., Lisziewicz J. (2000) Structured treatment interruptions to control HIV-1 infection. Lancet 355: 2878.
  • 16
    Rodenburg C.M., Li Y., Trask S.A., et al . (2001) The UNAIDS and NIAID Networks for HIV Isolation and Characterization. Near full-length clones and reference sequences for subtype C isolates of HIV-1 from three different continents. AIDS Res Hum Retro 17: 1618.
  • 17
    Fulcher J.A., Hwangbo Y., Zioni R., et al . (2004) Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection. J Virol 78: 788393.
  • 18
    Potter S.J., Lemey P., Dyer W.B., et al . (2006) Genetic analyses reveal structured HIV-1 populations in serially sampled T lymphocytes of patients receiving HAART. Virology 348: 3546.
  • 19
    Shankarappa R., Margolick J.B., Gange S.J., et al . (1999) Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73: 10489502.